Compare STXS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | PLX |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.7M | 168.4M |
| IPO Year | 2004 | 1996 |
| Metric | STXS | PLX |
|---|---|---|
| Price | $1.79 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | 469.6K | ★ 628.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | $29,346,617.00 | ★ $52,744,000.00 |
| Revenue This Year | $28.22 | $36.81 |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | $10.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.59 | $1.36 |
| 52 Week High | $3.59 | $3.19 |
| Indicator | STXS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 63.76 |
| Support Level | $1.74 | $2.06 |
| Resistance Level | $1.99 | $2.42 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 51.28 | 84.21 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.